Alphageneron to Participate in the ROTH Virtual Healthcare Private Company Forum on June 28th, 2021

By in
325
Alphageneron to Participate in the ROTH Virtual Healthcare Private Company Forum on June 28th, 2021

CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) — Alphageneron Pharmaceuticals, Inc. (“Alphageneron” or the “Company”), a privately-held clinical-stage biopharmaceutical company developing autologous and allogeneic Natural Killer (NK) cellular and antibody therapeutics announced that Robert Brooks, JD, founder and Chief Executive Officer of Alphageneron, will participate in the ROTH Healthcare Private Company Forum to be hosted virtually on Monday, June 28, 2021.

Alphageneron’s CEO, Robert Brooks will speak on the Cancer Panel 2, entitled “Natural Killer Cell Approaches To Eradicate Tumors,” as one of the presenting companies on the panel with “proof of concept” data utilizing NK cells against solid tumors. Mr. Brooks, will discuss a prior completed Phase IIa Clinical Trial with Advanced non-small lung cancer (NSCLC) patients, receiving autologous Hsp70 targeted NK Cell therapy (ENKASTIM™), after radio-chemotherapy, in Germany. The Company is planning a Phase IIa Clinical Combination Trial with Advanced NSCLC patients receiving ENKASTIM™ and PD (L)-1 checkpoint inhibitors, after Standard of Care, in the United States. Alphageneron is also planning a Phase I clinical Combination trial with Metastatic Colorectal cancer with allogeneic donor genetically edited NK cell therapy, (ANKASTIM™) in the United States.

Date:Monday January 28, 2021
Time:12pm-1pm EDT

To register for this virtual event click www.roth.com/healthcareprivateday or please contact Gerald Roger, c/o Trinity Capital Advisers  Tel. 347-730-5108, or email jerry.alain@trinitycapitaladvisers.com

Click Here to Read Original Article